跳至主要内容
临床试验/NCT02832024
NCT02832024Unknown不适用

Clinical Study of Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis

Xuanwu Hospital, Beijing1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
120
试验地点
1
主要终点
Primary Patency Rate

研究概览

简要总结

This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery).

详细描述

This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provides written informed consent Willing to comply with follow-up evaluations at specified times Has claudication or rest pain due to peripheral arterial In-stent restenosis Disease located within the femoropopliteal artery Patient has a In-stent restenosis lesion(s) with >50% stenosis documented angiographically Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater.

排除标准

  • They were excluded if they had one or more of the following:
  • Acute or subacute lower limb ischemia;
  • Severe calcification lesions;
  • Total occlusions lesions more significant than 10 cm or total occlusion lesions with a suspicion of subintimal wire recanalization
  • untreated ipsilateral iliac artery stenosis>70%, or the distal runoff artery <1 root;
  • Previously lower extremity intervention or surgical graft artery bypass;
  • Severe renal insufficiency, creatinine level greater than 2.5 mg/dL;
  • The patient's platelet count is less than 100,000/uL, antiplatelet or anticoagulant contraindications to required medications;
  • Patients with immune system diseases or malignant tumours;
  • ongoing active infection
  • decompensated congestive heart failure or acute coronary syndrome;
  • Unwillingness to return for future follow-up visits

结局指标

主要结局

Primary Patency Rate

时间窗: 12 months

Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis \>50% with a peak systolic velocity ratio \>2.4 as measured by Duplex ultrasound.

次要结局

  • Technical success(1 day)
  • Major Adverse Events(12 months)
  • freedom from clinically-driven TLR(12 months)
  • Limb Salvage Rate(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验